Oxaliplatin News and Research

RSS
Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Innovative compound kills cancer cells, minimizes damage to normal tissues

Innovative compound kills cancer cells, minimizes damage to normal tissues

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park receives more than $15 million in grants for cancer research

Processed aconite root could relieve neuropathic pain in murine peripheral neuropathy

Processed aconite root could relieve neuropathic pain in murine peripheral neuropathy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

SLU researchers turn off excruciating chemo pain in animal model

SLU researchers turn off excruciating chemo pain in animal model

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery

Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery

Study suggests revolutionary way to make cancer cells more susceptible to existing chemotherapies

Study suggests revolutionary way to make cancer cells more susceptible to existing chemotherapies